HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

etanercept biosimilar SB4

Networked: 8 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
- Peptides: 82426
  - Peptide Fragments: 373
    - Immunoglobulin Fragments: 976
      - Immunoglobulin Fc Fragments: 295
        Etanercept: 4749
        etanercept biosimilar SB4: 8
Complex Mixtures: 1906
- Biological Products
  - Biosimilar Pharmaceuticals: 1758
    - etanercept biosimilar SB4: 8

Experts

1.	Bianchi, L: 2 articles (11/2019 - 01/2019)
2.	Giunta, A: 2 articles (11/2019 - 01/2019)
3.	Girolomoni, G: 2 articles (01/2019 - 01/2018)
4.	Abad Hernández, Miguel Angel: 1 article (03/2021)
5.	Addison, Janet: 1 article (03/2021)
6.	Cantagrel, Alain: 1 article (03/2021)
7.	Farouk Rezk, Mourad: 1 article (03/2021)
8.	Freudensprung, Ulrich: 1 article (03/2021)
9.	Krüger, Klaus: 1 article (03/2021)
10.	Selmi, Carlo: 1 article (03/2021)

Related Diseases

1.	Rheumatoid Arthritis 11/01/2022 - "To better inform clinicians about the use of etanercept biosimilar (SB4) in patients with rheumatoid arthritis (RA), COMPANION-B, a prospective real-world observational study, evaluated the effectiveness of the voluntary switch from originator (etanercept, ETN) to SB4 in patients with stable RA (low-disease activity/remission). " 01/01/2023 - "Our objective was to compare drug effectiveness and drug persistence in the treatment of rheumatoid arthritis (RA), assessing the etanercept biosimilar SB4 in efficacy and safety compared with reference etanercept in a Phase III, randomized controlled trial. " 03/01/2021 - "The objective of this non-interventional study was to evaluate the effectiveness and safety of the etanercept biosimilar SB4 (BenepaliTM) following transition from reference etanercept in patients with rheumatoid arthritis (RA) or axial spondyloarthritis (axSpA). " 01/01/2018 - "Comparison of injection-site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study."
2.	Psoriatic Arthritis 11/01/2019 - "Etanercept biosimilar SB4 in the treatment of plaque-type psoriasis and psoriatic arthritis: a single-centre, observational, retrospective, real-life study." 11/01/2020 - "Background: Currently, there are no studies specifically aimed at investigating the effectiveness of etanercept biosimilar SB4 in psoriatic arthritis (PsA).Objectives: Our primary objective was to verify the ability of SB4 to maintain low disease activity in patients switching from reference etanercept to SB4 after 1 year of treatment with this last drug.Methods" 11/01/2020 - "Effectiveness of etanercept biosimilar SB4 in maintaining low disease activity in patients with psoriatic arthritis switched from etanercept originator: an open-label one year study."
3.	Psoriasis (Pustulosis Palmaris et Plantaris) 01/01/2019 - "Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry." 11/01/2019 - "Etanercept biosimilar SB4 in the treatment of plaque-type psoriasis and psoriatic arthritis: a single-centre, observational, retrospective, real-life study."
4.	Axial Spondyloarthritis 03/01/2021 - "The objective of this non-interventional study was to evaluate the effectiveness and safety of the etanercept biosimilar SB4 (BenepaliTM) following transition from reference etanercept in patients with rheumatoid arthritis (RA) or axial spondyloarthritis (axSpA). "
5.	Injection Site Reaction 01/01/2018 - "Comparison of injection-site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study."

Related Drugs and Biologics

1.	Etanercept (Enbrel)